Target and tissue selectivity of PROTAC degraders
The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Targeted protein degradation (TPD) strategies have revolutionized how scientists tackle challenging protein targets deemed undruggable with traditional small molecule inhibitors. Many promising campaigns to inhibit proteins have failed due to factors surrounding inhibition selectivity and targeting of compounds to specific tissues and cell types. One of the major improvements that PROTAC (proteolysis targeting chimera) and molecular glue technology can exert is highly selective control of target inhibition. Multiple studies have shown that PROTACs can gain selectivity for their protein targets beyond that of their parent ligands via optimization of linker length and stabilization of ternary complexes. Due to the bifunctional nature of PROTACs, the tissue selective nature of E3 ligases can be exploited to uncover novel targeting mechanisms. In this review, we provide critical analysis of the recent progress towards making selective PROTAC molecules and new PROTAC technologies that will continue to push the boundaries of achieving selectivity. These efforts have wide implications in the future of treating disease as they will broaden the possible targets that can be addressed by small molecules, like undruggable proteins or broadly active targets that would benefit from degradation in specific tissue types.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, PROTAC technology leverages E3 ligases, which may be selectively expressed in certain tissues, to drive the targeted degradation of specific targets,520 offering significant opportunities for AD treatment.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [520]
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy
Klán, P., Šolomek, T., Bochet, C. G., Blanc, A., Givens, R., Rubina, M., Popik, V., Kostikov, A., & Wirz, J. (2013) · Chemical Reviews · doi:10.1021/cr300177k · Cited by 1,827
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Research works printed but not linked: 1
- Chomez, 2001, Cancer Res., 61, 5544
Cited by
Items 101–200 of 324
Cheng, B., Ding, Z., Hong, Y., Wang, Y., Zhou, Y., Chen, J., Peng, X., & Zeng, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117347 · Cited by 17
Xu, M., Chen, J., Wang, S., Xu, L., Wu, X., Yu, J., Ma, F., & Shi, L. (2025) · ACS Macro Letters · doi:10.1021/acsmacrolett.4c00789 · Cited by 18
FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia
Li, W., Zhao, Y., Wu, D., Chen, Z., Qing, Y., Yang, F., Ji, F., Zhang, L., Sau, L., Chen, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv7648 · Cited by 20
Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety
Wang, K., Zhou, K., Zhong, N., Cao, L., Li, Z., Xiao, Y., Wang, G.-R., Huo, F., Zhou, J., Liu, B., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122635 · Cited by 18
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Development of PROTACS degrading KRAS and SOS1
Hamilton, G., Eggerstorfer, M.-T., & Stickler, S. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.051653 · Cited by 18
PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer
Meng, X.-L., Hu, X., Gao, S., Jia, W., Zhang, S., Zhang, S., Wang, X., Ma, S., & Qin, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00226 · Cited by 18
Nalawansha, D. A., Mazis, G., Husemoen, G., Ashton, K. S., Deng, W., Wurz, R. P., Tran, A. T., Lanman, B. A., Xie, J., Guenette, R. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63128-4 · Cited by 19
Self-citationNanoparticle-mediated targeting chimeras transform targeted protein degradation
Liu, Y., Xia, X., Zhang, Y., Zheng, M., Leong, K. W., & Shi, B. (2026) · Nature Nanotechnology · doi:10.1038/s41565-025-02081-1 · Cited by 18
Zhang, R., Xie, S., Ran, J., & Li, T. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31255 · Cited by 15
Fragment-based approaches to discover ligands for tumor-specific E3 ligases
Yim, J., Kim, S., Lee, H. H., Chung, J. S., & Park, J. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2415310 · Cited by 17
Development of Versatile Solid-Phase Methods for Syntheses of PROTACs with Diverse E3 Ligands
Xu, H., Kurohara, T., Ohoka, N., Tsuji, G., Inoué, T., Naito, M., & Demizu, Y. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117293 · Cited by 16
Targeted protein degradation technologies: Emerging mechanisms and nano-based innovations
Hou, M., Zhao, R., Wang, S., Jiang, B., & Yan, X. (2025) · Nano Research · doi:10.26599/nr.2025.94907983 · Cited by 15
Recent advances in targeting protein degradation for tumor immunotherapy
Li, S., Jin, Y., Wu, H., Yuan, H., & Zhao, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01765-4 · Cited by 14
Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia
Wu, T., Hu, J., Zhao, X., Zhang, C., Dong, R., Hu, Q., Xu, H., Shen, H., Zhang, X., Zhang, Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00335 · Cited by 14
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
Vicente, A. T. S., & Salvador, J. A. R. (2024) · MedComm · doi:10.1002/mco2.575 · Cited by 14
Emerging magic bullet: subcellular organelle-targeted cancer therapy
Yan, Y., Zhang, Y., Liu, J., Chen, B., & Wang, Y. (2024) · Medical Review · doi:10.1515/mr-2024-0044 · Cited by 18
Xiao, Y., Jiang, T., Qi, X., Zhou, J., Pan, T., Liao, Q., Liu, S., Zhang, H., Wang, J., Yang, X., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138292 · Cited by 16
Sandhof, C. A., Murray, H. F. B., Silva, M. C., & Haggarty, S. J. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00499 · Cited by 14
Advancements in PROTAC-based therapies for neurodegenerative diseases
Kong, D., Meng, L., Lin, P., & Wu, G. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2463310 · Cited by 19
VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation
Mangano, K., Guenette, R. G., Hill, S., Li, S., Liu, J. J., Nadel, C. M., Archunan, S., Sadhukhan, A., Kapoor, R., Yang, S. W., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.02.002 · Cited by 15
Self-citationJu, Y., Song, H., He, Y., Lo, Y., Fan, Z., & Lu, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01022 · Cited by 15
Wang, D., Liu, Y., Chen, Y., Dai, C., Hu, W., Han, J., Li, Z., Yin, F., Zhang, Y., & Chen, S. (2025) · Advanced Science · doi:10.1002/advs.202510197 · Cited by 16
Jiang, Q., Hu, Y., Liu, Q., Tang, Y., Wu, X., Liu, J., Tu, G., Li, G., Lin, X., Qu, M., et al. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2185247 · Cited by 14
Xie, H., & Zhang, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116168 · Cited by 16
Cui, Y., Chen, Y., Li, H., Zhang, W., Wang, X., Xia, M., Gan, N., Zhou, Y., Li, M., Zhang, H., et al. (2025) · Research · doi:10.34133/research.0922 · Cited by 16
Next-generation isoform-selective fibroblast growth factor receptor inhibitors
Chen, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.09.004 · Cited by 14
Development of natural product-based targeted protein degraders as anticancer agents
Chen, C., Feng, Y., Zhou, C., Liu, Z., Tang, Z., Zhang, Y., Li, T., Gu, C., & Chen, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107772 · Cited by 14
Wang, Y., Wang, M., Lan, M., Zhang, Y., Jiao, Y., Zhang, S., Yang, Y., Li, J., Wei, M., Cao, S., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01621 · Cited by 15
FGFs/FGFRs and neuroinflammatory diseases: mechanism, drug therapies and delivery systems
Wang, J., Xing, L., Song, Y., Yang, Y., Zhang, Y., Ma, H., Su, B., Su, L., Ma, C., Liu, M., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.024 · Cited by 14
Recent Advances in PROTAC Technology Toward New Therapeutic Modalities
Yokoo, H., Naganuma, M., Oba, M., & Demizu, Y. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200828 · Cited by 16
A comprehensive primer and review of PROTACs and their In Silico design
Zattoni, J., Vottero, P., Carena, G., Uliveto, C., Pozzati, G., Morabito, B., Gitari, E., Tuszyński, J. A., & Aminpour, M. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108687 · Cited by 16
Yuan, Z., Guo, M., Zhang, Y., Deng, Y., Sun, B., Hou, Y., Wang, X., Jin, X. J., Liu, Y., Shi, B., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02392-1 · Cited by 14
Xie, W., Sun, W., Li, Q., Dang, Y., Ma, L., Liu, Y., Zhang, H., Qu, F., & Tan, W. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2424500122 · Cited by 15
Giardina, S. F., Valdambrini, E., Singh, P. K., Bacolod, M. D., Babu-Karunakaran, G., Peel, M. R., Warren, J. D., & Barany, F. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02097 · Cited by 13
Targeted degradation of LRG1 to attenuate renal fibrosis
Fan, L., Qi, Y., Yang, X., Xu, Y., Zhang, Y., Wang, L., Zhu, A., Zhang, L., Song, J., Du, S., et al. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100941 · Cited by 20
Li, S., Pan, W., Tao, C., Hu, Z., Cheng, B., Chen, J., & Peng, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02106 · Cited by 11
Hypoxia-sensitive macrocycle inclusion complexes for targeted protein degradation
Lin, J., Wang, W., Ying, A., Chen, Z., Zhang, D., Ding, C., Zeng, X., Guo, D., & Chen, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113921 · Cited by 11
A Medicinal Chemistry Perspective on Lactate Dehydrogenase: Current Status and Future Directions
Pan, W., Tao, C., Wu, Y., & Jiang, F. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00182 · Cited by 12
O’Hanlon, J. A., Gutsche, K., Müller, J. E., Prusty, N. R., Mirza, A. R., Roumeliotis, T. I., Yang, H., Stubbs, M., Hallett, S. T., Eing, L., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03024 · Cited by 13
A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
Kong, Y., Zhao, X., Wang, Z., Yuan, S., Chen, S., Lou, S., Ma, S., Li, Y., Wang, X., Ge, Y., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0719 · Cited by 12
Huang, Q., Hu, L., Chen, H., Yang, B., Sun, X., & Wang, M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01802 · Cited by 11
Li, B., Qi, J., Cao, Y., Long, Y., Wei, Z., Wang, W., Hu, S., Wang, Y., Zhu, Q., Hu, X. J., et al. (2025) · Advanced Science · doi:10.1002/advs.202411752 · Cited by 14
Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment
Hussain, M. S., Zhang, L., Rana, A. J., Maqbool, M., Ashique, S., Khan, Y., Jakhmola, V., Hanbashi, A., Mawkili, W., & Khan, G. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2533113 · Cited by 11
Jiang, X., Chen, Y., Gao, Y., Rong, R., Lai, Y., Zhu, Z., & Xu, Z. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115808 · Cited by 10
León, R. G., & Bassham, D. C. (2023) · Pest Management Science · doi:10.1002/ps.7741 · Cited by 10
Paik, H., Oh, C., Hussain, S., Seo, S., Park, S. W., Ko, T. L., & Lee, A. (2024) · Database · doi:10.1093/database/baae111 · Cited by 16
Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation
Miao, J., & Zhang, Z. (2024) · ChemMedChem · doi:10.1002/cmdc.202300669 · Cited by 9
Yi, L., Zhang, Z., Zhou, W., Zhang, Y., Hu, Y., Guo, A., Cheng, Y., Qian, Z., Zhou, P., & Gao, X. (2024) · Advanced Science · doi:10.1002/advs.202409753 · Cited by 10
Current strategies for senescence treatment: Focused on theranostic performance of nanomaterials
Cong, Y., Li, X., & Hong, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113710 · Cited by 10
Peng, S., Zhang, Q., Tian, H., Zhang, J., Deng, J., Qi, H., Wu, D., Du, T., Zhang, K., Ge, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00679 · Cited by 9
Elucidating biased signaling in class A GPCRs
Xu, N., Legall, E., Johnson, R. H., Zhu, L., & Liu, W. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.10.008 · Cited by 10
De Novo Design of Hexamer‐Linker Dual‐Action Nano‐PROTAC for Tumor‐Specific Ferroptosis
Zhang, N., Wen, Z., Cai, M., Zhou, K., Li, H., Liu, Y., Wu, S. W., Xia, Y., An, H., & Wang, H. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202509924 · Cited by 19
Nafie, M. S., Diab, M. K., Yassen, A. S. A., Elshamy, A. M., Tohamy, M. R. E., Tawfik, H. O., & Fahmy, S. A. (2025) · Drug Development Research · doi:10.1002/ddr.70192 · Cited by 10
New-generation advanced Nano-PROTACs as potential therapeutic agents in cancer therapy
Zhang, J., Li, Y., Jin, H., Yang, P., Min, H., Song, J., & Qi, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114673 · Cited by 10
Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs
Yao, R., Luo, T., & Wang, M. (2023) · ChemBioChem · doi:10.1002/cbic.202300413 · Cited by 9
Palomba, T., Tassone, G., Vacca, C., Bartalucci, M., Valeri, A., Pozzi, C., Cross, S., Siragusa, L., & Desantis, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214218 · Cited by 11
Liu, Y., Sun, Q., & Wei, X. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2342522 · Cited by 8
Engineering brain-penetrant PROTACs: Bridging molecular design and CNS delivery
Li, X., Li, J., Sun, Y., Yao, T., Lu, Y., Liu, S., Li, H., Shi, Y., Chen, L., Zhao, Y., et al. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115876 · Cited by 11
A Multi-Split-and-Mix Platform for a Variety of Targeted Protein Degradation
Wang, Y., Luo, Q., Xing, Y., Wang, R. Y., Yang, F., Cao, W., Li, Z., & Yin, F. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00444 · Cited by 7
Targeted protein degradation in autoimmune diseases: from mechanisms to therapeutic breakthroughs
Song, Y., Zhou, B., Long, J., & Peng, Y. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103475 · Cited by 9
Olazábal-Morán, M., Pérez, E., Esteban-Arranz, A., & Garrido, A. (2025) · Biomolecules · doi:10.3390/biom15091316 · Cited by 8
Zhang, Q., Liu, Y., Zhang, J., Dong, H., Pan, X., & Zhang, J. (2025) · Small · doi:10.1002/smll.202506562 · Cited by 7
Methods to characterize and discover molecular degraders in cells
Lin, Z., & Woo, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00261b · Cited by 7
DNA polymerase theta in cancer therapy: mechanism of action and modulator development
Wu, J., Xu, Y., & Xiao, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117513 · Cited by 6
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review
Viviano, M., Cipriano, A., Fabbrizi, E., Feoli, A., Castellano, S., Sbardella, G., Mai, A., Milite, C., & Rotili, D. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2327300 · Cited by 6
Advances in Ubiquitination and Proteostasis in Retinal Degeneration
Wei, J., Chen, X., Xiong, Y., & Gao, Y. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2907260 · Cited by 6
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Herbel, N., & Postel-Vinay, S. C. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70034 · Cited by 6
Site-resolved assessment of targeted protein degradation
Moreno-Ballesteros, R., Pembridge, T., Beniwal, G., & Virdee, S. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.06.002 · Cited by 5
The role of TRIM proteins in chronic inflammation-associated musculoskeletal diseases
Livshits, G., & Kalinkovich, A. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102837 · Cited by 8
Nanotechnology-based strategies for overcoming clinical limitations of PROTACs in cancer therapy
Cho, H., Kim, J., Lee, H.-Y., Kang, H., & Kim, K. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01162k · Cited by 6
Molecular glue degraders: Rational design, specificity engineering, and advanced delivery
Ma, L., Wang, N., Zhu, J., Wu, L., He, S., & Zhang, B. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.020 · Cited by 8
Zhang, N., Liang, J.-X., Hu, B.-N., Wang, Y., An, H., & Wang, H. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115861 · Cited by 6
Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
Yao, T., Zhou, Z., Wang, G., Zhu, Z., & Li, X.-N. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01853-2 · Cited by 6
Wang, Y., He, Y., You, Q., & Wang, L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104194 · Cited by 6
Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation
Rejili, M. S., Hussain, M. S., Haouala, F., Khan, Y., Maqbool, M., & Gupta, G. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109097 · Cited by 6
Medicinal Chemistry Education: Emphasize Fundamentals and Skillfully Integrate Knowledge
Du, S., Hu, X., Lindsley, C. W., & Zhan, P. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02622 · Cited by 5
ClpP-based MtPTAC technology enables targeted degradation of inner mitochondrial membrane proteins
Yao, Y., Wang, D., Gong, H., Jiang, R., Liu, Y., Liu, Y., Lai, X., Xu, Z., Zhou, W., Li, H., et al. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118350 · Cited by 4
Wang, X., Meng, R.-J., Cao, W.-J., Cheng, L., Zhang, J., & Chen, S. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118473 · Cited by 4
Luo, H., Ma, J., Yang, H., Hu, H., Xu, Z., Jin, L., Chen, J., Qian, C., Ju, J., Zhang, Y., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503988 · Cited by 7
Design of conditional and tumor-activated PROTACs for selective degradation in lung cancer
Lin, L., Zheng, F., Wei, H., Wu, X., Yan, H., & Ding, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118432 · Cited by 5
Expanding the druggable proteome strategies and innovations in targeted protein degradation
Ma, K., Liu, T., Huan, W.-B., Chen, K.-Z., & Qiao, S. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102945 · Cited by 4
PROTAC-powered synergistic tumor therapy
Wang, X., Zou, J., Tao, Y., Zhou, Z., Bian, C., Mao, Z., & Liu, Z. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.118678 · Cited by 4
Bi, T., Chen, L., Wang, T., Miao, W., Zhai, S., Huang, R., Sun, Q., Chen, Y., Su, H., Zhou, J., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04036-7 · Cited by 5
A pharmacological modality to sequester homomeric proteins
Livnah, E., Suss, O., Rogel, A., Gilat, A., Abdan, Y., Villegas, J. A., Gabizon, R., Nadir, A., Shamir, Y., Steinman, N. Y., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02141-0 · Cited by 4
PROTACs for central nervous system disorders: challenges and opportunities
Zheng, N., Shao, J., Xiong, B., Wei, Y., Wang, X., Zhou, Y., Song, Z., Zhang, A., Xu, C., Zhao, Q., et al. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118703 · Cited by 4
Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD)
Banerjee, M., Detappe, A., & Lammers, T. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115922 · Cited by 4
Application of mass spectrometry for the advancement of PROTACs
Hao, Y., Zhang, B., & Chen, R. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116829 · Cited by 4
Synthesis of selective BCL-XL PROTAC and potent antitumor activity in glioblastoma
Liu, M., Sun, B., Niu, R., Zhang, Y., Li, X., Wang, J., Wang, X., & Yin, J. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102593 · Cited by 4
Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis
Lu, X., Wang, X., Liao, H., Sha, B., Zhang, Y., & Li, J. (2025) · Angewandte Chemie · doi:10.1002/ange.202510641 · Cited by 7
Xiong, S., Zhou, J., & Chng, W. J. (2025) · Blood · doi:10.1182/blood.2025028403 · Cited by 4
Guo, Y. L., Song, Y., Wang, H., Yang, L., Zhang, J., Shen, Z., Kan, W., Wang, Y., Duan, H., Geng, S., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.009 · Cited by 5
The Discovery of a Specific CKIP-1 Ligand for the Potential Treatment of Disuse Osteoporosis
Wei, Y., Wu, B., Liu, M., & Cui, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168870 · Cited by 4
Wei, T., Zhou, S., Jing, X., Liu, J., Sun, M., Zhao, Z.-H., Li, Q., Wang, Z., Yang, J., Zhou, Y., et al. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01830 · Cited by 4
Dai, Y., & Zhu, F. (2024) · Computer Science and Information Systems · doi:10.2298/csis240327039d · Cited by 4
Modulating the phosphorylation status of target proteins through bifunctional molecules
He, Q., Wang, Z., Wang, R., Lu, T., Chen, Y., & Lü, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104307 · Cited by 4
USP13: A therapeutic target for combating tumorigenesis and antitumor therapy resistance
Yi, L., Shahatiaili, A., Zhang, L., He, H. H., Chen, L., Zhang, Z., Gao, F., Shao, F., Gao, Y., & He, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140608 · Cited by 6
PROTACs improve selectivity for targeted proteins
Liu, L., Guan, X., Zhuo, J., Wu, X., & Han, X. (2025) · Acta Materia Medica · doi:10.15212/amm-2025-0015 · Cited by 4
Targeted Protein Degradation for Agricultural Applications: Rationale, Challenges, and Outlook
Fourches, D., Pilotte, J. R., Watts, B. E., Saltzberg, D. J., & Cicchillo, R. M. (2025) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.5c00111 · Cited by 3
Yang, J., Zhang, Y., Zhang, M., Xing, D., & Wang, C. (2025) · Materials Today Advances · doi:10.1016/j.mtadv.2025.100644 · Cited by 4
Metadata
- Authors
- Guenette, R. G., Yang, S. W., Min, J., Pei, B., & Potts, P. R.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Potts, Patrick Ryan
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2022
- Volume
- 51
- Issue
- 14
- Pages
- 5740-5756
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W4280616471
- Cited by
- 324
- References
- 133
- Citations by year
- 2026: 87 · 2025: 110 · 2024: 77 · 2023: 40 · 2022: 10
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- PROTACs, targeted protein degradation, tissue selectivity, E3 ubiquitin ligase, bifunctional molecules, linker optimization, undruggable proteins, small molecule drug discovery
- MeSH terms
- Ligands, Ubiquitin-Protein Ligases, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.